Search
Carmofur
go.drugbank.com/drugs/DB09010ApprovedWithdrawnCarmofur is a derivative of fluorouracil, and is an antineoplastic agent that has been used in the treatment of breast and colorectal cancer. Carmofur has been known to induce leukoencephalopathy.
Categories: Heterocyclic Compounds, 1-RingBromopride
go.drugbank.com/drugs/DB09018InvestigationalBromopride is a dopamine antagonist used as an antiemetic. Its prokinetic properties are similar to those of metoclopramide. It is unavailable in America or the United Kingdom.
Mixtures: ENZYMED®TABLETAS RECUBIERTASSynonyms: 4-amino-5-bromo-N-[2-(diethylamino)ethyl]-2-methoxybenzamideCytisine
go.drugbank.com/drugs/DB09028InvestigationalCytisine is a partial nicotinic acetylcholine agonist with a half-life of 4.8 hours. … Recent Phase III clinical trials using Tabex (a brand of Cytisine marketed by Sopharma AD) have shown similar efficacy to varenicline, but at a fraction of the cost.
Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingSynonyms: (1R,5S)-1,2,3,4,5,6-Hexahydro-1,5-methano-8H-pyrido[1,2a][1,5]diazocin-8-oneVedolizumab
go.drugbank.com/drugs/DB09033ApprovedInvestigationalVedolizumab is a recombinant humanized IgG1 monoclonal antibody directed against the human lymphocyte α4β7 integrin, a key mediator of gastrointestinal inflammation implicated in diseases like ulcerative … [A261576] Vedolizumab is administered by IV infusion over a period of 30 minutes; after the first dose, it is given again at two and six weeks and then every 8 weeks thereafter.
Products: ENTYVIO® 108 MG SOLUCIÓN INYECTABLE, ENTYVIO® (SUBCUTÁNEO) VEDOLIZUMAB 108 MG SOLUCIÓN INYECTABLEPembrolizumab
go.drugbank.com/drugs/DB09037ApprovedInvestigationalIt was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype containing a stabilizing S228P Fc mutation. … Pembrolizumab is a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptors.
Categories: PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsProducts: KEYTRUDA® 100 MG, KEYTRUDA 100 MG/4 ML IV INFUZYONLUK COZELTI İÇEREN FLAKON, 1 ADETBlinatumomab
go.drugbank.com/drugs/DB09052ApprovedInvestigationala short peptide linker. … [L46991,L46996] Blinatumomab has a short half-life, requiring patients to receive a continuous infusion over 4-week cycles using a portable mini-pump for optimum delivery.[A254826]
Categories: Bispecific CD19-directed CD3-directed T Cell EngagerProducts: BLINCYTO® 38.5 MCG/VIAL, BLİNCYTO 38,5 MCG İNFÜZYONLUK ÇÖZELTİ İÇİN KONSANTRE TOZ VE ÇÖZELTİ, 1 ADETIbrutinib
go.drugbank.com/drugs/DB09053ApprovedInvestigationalIt is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. … Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingSynonyms: 1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-oneIdelalisib
go.drugbank.com/drugs/DB09054ApprovedInvestigationalBy inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and … Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexSynonyms: 5-Fluoro-3-phenyl-2-((S)-1-(9H-purin-6-ylamino)-propyl)-3H-quinazolin-4-one, 5-fluoro-3-phenyl-2-[(1S)-1-(3H-purin-6-ylamino)propyl]quinazolin-4(3H)-oneAcipimox
go.drugbank.com/drugs/DB09055ApprovedInvestigationalAcipimox is a niacin derivative used as a hypolipidemic agent. … Acipimox inhibits the production of triglycerides by the liver and the secretion of VLDL, which leads indirectly to a modest reduction in LDL and increase in HDL.
Categories: Heterocyclic Compounds, 1-RingCorifollitropin alfa
go.drugbank.com/drugs/DB09066ApprovedInvestigationalCorifollitropin alfa is produced by a method known as ‘recombinant DNA technology’. … In July 2014, Merck announced the receipt of a Complete Response Letter (CRL) from the U.S. FDA for its New Drug Application for this drug.
Products: GONAL-F ® 300 UI (22 MCG)/0.5 ML INYECTOR (FOLITROPINA ALFA (R-HFSH)), GONAL -F ® INYECTOR 450 UI (33MCG)/0.75ML.